Roche AmpliChip to Help Merck Investigate Role of p53 DNA Damage in Cancer Rx Response
February 24, 2010
Roche AmpliChip to Help Merck Investigate Role of p53 DNA Damage in Cancer Rx Response
Merck will use Roche's microarray-based AmpliChip p53 test in clinical studies to assess which cancer patients are likely to respond to drugs that are currently in development.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Roche Grants Merck Access to p53 Chip
February 17, 2010 / GenomeWeb Daily News - Merck to Use Roche's p53 AmpliChip for Cancer Research
February 23, 2010 / BioArray News - After Decade as CRO, Shanghai Biochip Plans Move into Chinese Molecular Dx Market
December 18, 2012 / BioArray News - During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter - PGx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 14, 2012 / Pharmacogenomics Reporter